Acquisition Overview - VitalHub Corp. has completed the cash acquisition of Induction Healthcare Group PLC through a court-sanctioned scheme of arrangement, valuing Induction at approximately £9.7 million [1][4] - The acquisition price was £0.10 in cash for each Induction share [4] Induction's Business and Financials - Induction provides software solutions that enhance care delivery and patient journeys in hospitals, with key products including Zesty and Attend Anywhere [3][6] - For the six-month period ending September 30, 2024, Induction reported revenues of £5.4 million, a gross margin of 78.2%, and an adjusted EBITDA loss of £0.9 million [4] - Zesty generated revenues of £2.0 million, while Attend Anywhere generated revenues of £3.2 million, with £0.2 million from discontinued operations [4] - As of the acquisition closing date, Zesty had an Annual Recurring Revenue (ARR) of £2.2 million, and Attend Anywhere had virtual care recurring revenue of £4.6 million [4][14] Strategic Rationale - The CEO of VitalHub stated that the Induction product set, particularly the Zesty platform, is highly complementary to VitalHub's existing solutions, aiming to enhance value for healthcare partners and improve patient outcomes [5] - VitalHub's growth strategy includes targeting organic opportunities and pursuing an aggressive M&A plan [5]

Core Viewpoint - VitalHub Corp. has announced a cash acquisition of Induction Healthcare Group PLC, valuing Induction at approximately £9.7 million, with each shareholder entitled to receive £0.10 in cash for each share held [1] Company Overview - Induction provides software solutions that enhance care delivery and patient journeys in hospitals, allowing healthcare providers to deliver care both remotely and face-to-face [3][16] - Key products include Zesty, a patient engagement platform, and Attend Anywhere, a video consultation platform [4][5] Financial Performance - For FY24, Induction reported revenues of £14.4 million, a gross margin of 78.4%, and an adjusted EBITDA loss of £0.3 million [6] - For H1 FY25, revenues were £5.4 million, with a gross margin of 78.2% and an adjusted EBITDA loss of £0.9 million [7] Strategic Rationale - VitalHub views Induction's Zesty platform as complementary to its existing offerings, aiming to enhance product diversity and improve patient outcomes [8] - The acquisition is expected to expand VitalHub's market reach in the UK, Europe, Canada, the Middle East, and Australia [9] - Induction is anticipated to benefit from being part of a larger, well-capitalized enterprise, enabling effective implementation of strategic initiatives [10] Acquisition Details - The acquisition will be executed through a court-approved scheme of arrangement, requiring approval from Induction shareholders and the Court [11][12] - Induction's directors recommend shareholders vote in favor of the scheme, with irrevocable commitments received for approximately 44.3% of Induction's shares [13] - The transaction is expected to close by July 31, 2025, with a long stop date of September 30, 2025 [13]